Clinical trial phases: what each one means for you

Clinical trials of new cancer treatments move through phases, and each phase asks a different question. A phase one trial is the first time a new treatment is tested in people, usually in a small group. Its main aim is to find out whether the treatment is safe and how much can be given, not to test whether it treats the cancer. A phase two trial gives the treatment to a larger group with a particular cancer to see whether it has any effect and to learn more about side effects. A phase three trial compares the new treatment with the current standard in a large group. A phase four study follows a medicine after approval to watch for rarer or longer-term effects.

Which phase you are being offered matters enormously, so ask directly. The information sheet should state the phase clearly, and the trial's entry on the Clinical Trials Registry – India also records it. Phase one trials are often offered to people whose cancer has stopped responding to standard treatments, and they may include people with many different cancers. Phase two trials usually focus on one cancer type. Phase three trials may be offered at diagnosis or at any point in treatment, and often use randomisation, where a computer decides your group. Some trials combine two phases, such as a phase one and phase two study, so ask what each part involves for you.

The risk profile changes across phases. In phase one, the least is known, side effects may be unexpected, and the chance of personal benefit is uncertain, because the purpose is to find a safe amount. In phase two, more is known about safety, but whether the treatment works is still an open question. In phase three, the treatment has usually shown some promise, and the comparison group receives standard care, yet nobody knows which will turn out better. In every phase, taking part is voluntary, a trial may not benefit you personally, and you can withdraw at any time without losing your standard care. Your treating oncologist can explain what the phase means in your situation.

Phase one is about safety and amount

It is not mainly designed to treat the cancer.

Phase three compares with standard care

The control group receives real treatment.

Always ask which phase

It changes what joining means for you.

It cannot tell you what a particular trial involves or how its treatment would affect you. Every trial has its own design, and only its documents explain it.

It also cannot tell you whether a trial in any phase is right for you. Your oncologist can help you decide.

Why phase one is different

A phase one trial is dose-finding, not treatment-seeking. The research question is how much of a new treatment can be given safely. Some people may see their cancer respond, but that is not the purpose, and it cannot be expected. Joining is a contribution to knowledge, and it deserves careful thought.

How amounts are found in phase one

Often the first small group receives a low amount. If it is tolerated, the next group receives a little more, and so on, while side effects are watched closely. People who join early may receive amounts that are too low to act on the cancer. This is how safety is protected for everyone.

Why phase one needs so many checks

Because so little is known, phase one trials usually involve frequent blood tests, heart tracings, scans and sometimes short hospital stays. For families who live far away, this can be demanding. Ask for the full visit schedule so you can judge whether it is manageable.

Phase zero studies

Occasionally, researchers run very small early studies using tiny amounts of a medicine to see how it behaves in the body. These are called phase zero studies, and they are not intended to treat. They are uncommon, and the information sheet will explain the purpose if one is offered.

What phase two can and cannot show

A phase two trial may show that a treatment shrinks some cancers or slows them. It usually cannot show that people live longer or better than with standard care, because there is often no comparison group. Promising phase two results sometimes do not hold up in larger phase three trials.

Why phase three uses randomisation

To compare treatments fairly, the groups must be similar. A computer allocates each person by chance, so neither you nor your doctor chooses. This can feel uncomfortable, but it is the most reliable way to learn whether a new treatment is better, similar or worse than the current standard.

Placebos in later phases

In cancer, phase three trials rarely give a placebo alone when an effective treatment exists. More often, a dummy is added to standard treatment so nobody knows who is receiving the new medicine. The consent form must tell you whether a placebo is used and what each group receives.

Phase four after approval

Once a medicine is approved, it is used in far more people than in trials. Phase four studies watch for rare or long-term side effects and learn how the medicine works in everyday practice. Taking part may involve questionnaires or extra checks while you receive approved treatment.

Indian oversight in every phase

Trials of new medicines in India, in any phase, need approval from the national drug regulator, review by an ethics committee and registration on the Clinical Trials Registry – India before enrolment. These steps do not remove risk, but they check that the study is justified and participants are protected.

Combined phase trials

Some trials run two phases together, starting with a safety part and moving into a part that looks for effect. You may join at either stage. Ask which part you would join, because the aims, checks and uncertainty differ between the two parts of the same study.

Talking to your family

Explaining phases to relatives can be hard, especially when hope is high. It may help to show them the information sheet and describe the main question of the trial in simple words. Bringing a relative to discussions means someone else also hears the difference between each phase directly.

Withdrawing in any phase

Whatever the phase, you may leave a trial at any time without giving a reason. The team may suggest a final safety check, which is sensible. Your treating oncologist will then discuss standard options, and leaving will not affect the quality of the care you receive afterwards.

What to do next

Ask which phase the trial is and what its main question is, request the full visit schedule, check the entry on CTRI, and discuss with your treating oncologist and family what that phase means for you before deciding.